ASTRO releases breast RT guide

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 9
Volume 19
Issue 9

ASTRO has published evidence-based guidelines to define appropriate fractionation of whole-breast irradiation.

ASTRO has published evidence-based guidelines to define appropriate fractionation of whole-breast irradiation. The guidelines state that hypofractionated whole-breast irradiation is effective for patients with early-stage breast cancer who meet certain criteria, including age 50 years and older and stage T1-2 N0 disease. Also, eligible patients will not have received chemotherapy. In addition, the radiation oncologist must be able to provide a relatively uniform delivery of the radiation dose and the ability to exclude the heart from the path of the radiation beam.

For patients who do not meet these criteria, there was not enough evidence to reach a consensus for or against the use of hypofractionated whole-breast irradiation (Int J Radiat Oncol Biol Phys online, July 15, 2010).

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.